Performance says 2nd late-stage research study for hair loss therapy reached main objective (NASDAQ: CNCE).

Md Babul Hosen/iStock by way of Getty Pictures Scientific-stage biotech Online efficiency Prescription medicines (NASDAQ: CNCE) traded ~ 7% larger within the pre-market Monday after the corporate presented that its second Section 3 trial for CTP-543 reached its primary endpoint in patients with alopecia location. An autoimmune dysfunction, alopecia location causes irregular or complete scalp loss of hair. [
Read More
Komentarze
Prześlij komentarz